United States · Resolution · SRES
S.Res. 218 (102nd)
A resolution urging the Food and Drug Administration to review and revise the approval process for experimental drugs.
Introduced
12 November 1991
Last action
—
Status
Referred to the Committee on Labor and Human Resources.
Sponsors
—
Subjects
Discovery layer
Source updated
21 April 2025
Summary
Declares that it is the sense of the Senate that: (1) the Food and Drug Administration (FDA) is to be commended for its proposed changes to the drug approval process; and (2) the FDA should review the approval process, incorporate ways for more timely, yet safe approval, and for access by all terminally ill patients to experimental drugs awaiting approval.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
2 official files
Introduced in Senate (text)
Introduced in Senate (text)
Introduced in Senate · EN
Introduced in Senate
summary · EN · 12 November 1991
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.congress.gov/bill/102nd-congress/senate-resolution/218
- Open data entity: https://api.congress.gov/v3/bill/102/sres/218